Utilico Insights - Jacqueline Broers assesses why Vietnam could be the darling of Asia for investors. Watch the full video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
T20. sort of trade now pay later arrangement. 20 days credit
T20s?
yep, me too, though I'm onto T20s as out of readies....!
i managed to add a cheeky topup at 81.20p so happy with that. anything below 85 and im happy to add if funds are there.
nice test, didnt get to place the limit order in time to get the 80p, when i get paid next week il set a limit order at 78p to finish my last top up.
either im happy with what iv got but its dropping into the too good to be true territory now
I am also going to hold on for my last tranche as you never know may get them bit cheaper, if not I am happy with the current holding.
iv set a limit order to buy at 80p for my final top up.
if it hits it great, if it doesn't i still have a large holding
Amazing how fast the price is moving without much volume.
Keeping close eye for my final top up.
I agree phantom ,AN is one of the reasons i have so much faith in angle. Ill be looking to top up if the prices stay as good over the coming weeks
Tom do not worry AN will not sell AGL off cheap. He's already fought off a buy out attempt many years ago. Braveheart attempted to rally support from large investors, but it failed AN was stubborn. It may have even been before Parsortix was to be used for CTC capture. Parsortix original design use was for collecting fetal cells in mothers blood, nothing to do with cancer. Rumor has it he rejected £2.50
By way of a small example, on Monday Regeneron received approval from the FDA for expanded use of their anti-PD-1 cancer drug Libtayo to include the first-line treatment of patients with advanced non-small cell lung cancer whose tumors have with programmed death-ligand 1, or PD-L1, expression of at least 50%.
A simple and cost effective way of measuring PD-L1 status may come in handy for Regeneron (or the insurers being asked to pay for Libtayo)....enter Parsortix via the US lab service.
we should try and create a massive voting block to resist any take overs, Phantom can lead! lol
good idea phantom. if it stays this low in the coming weeks il be topping up again too
Exactly Miavoce, what is it only 1 in 4 with the correct status? So 75% of a 100k treatment is wanted at present
Think I've talked myself into buying more tomorrow, but I shouldn't, got too many as it is
Insurers in the US will also start demanding a PD-L1 status test before approving spend on mega expensive checkpoint inhibitors which will only work on patients with a particular PD-L1 status.
Basically Parsortix is making a lot of things possible that couldn't be done before, and there is real demand for these things. Of course it will take time for sales volumes to grow, but AGL will be bought out by a big player based on the future financial potential long before revenue hits high levels.
That is the next stage down the line the Pathology lab and we want a piece of that also
true Phantom and the Abbott deal talked about a tenfold mark up to 3000 dollars for this as it will still be way cheaper than a surgery
Another point to consider when talking about the US, is that it is private health insurers that are footing the bill for biopsies. They will demand a £150 Parsortix blood test instead of a multi thousand dollar surgical biopsy. This is what FDA approval is all about, it will certify Parsortix is an unarguable alternative
exactly phantom and most biopsys like that cost a lot of money. This allows Angle to charge a healthy premium for parsortix and still save everyone a lot of money
Lets use an example, years ago my father found a lump on his neck. He saw GP got referred to a specialist, had a second appointment that required an operating room a surgeon a local anaesthetic, clean up afterwards of equipment etc. Al that could be replaced with blood test at either the GP or specialist. It is going to save a fortune
again screening comes down to probability . Men can get breast cancer but we make up 1/100 of the cases. It isn't worth doing a mammogram on every guy because the risk is already low and the cost involved wouldn't justify it .
Its all about the benefits of screening with parsortix vs the cost.
if parsortix can shown to be a useful screening tool without costing an arm and a leg then it has a chance of being used. Prostate is the most promising from the same blood draw you could test PSA and CTC's.
Since other blood biopsy techs cost a lot more there would be no competition in this area too
yes correct, i think the idea is phantom that a patient who has shown a mass on a mammogram ,will have a liquid biopsy instead of a actual biopsy. I dont think they will replace the mammogram anytime soon as a screening tool , no mass no cancer i guess. But the liquid biopsy will save the need for a tissue biopsy or often unneeded mastectomy and help select the best treatment
i think from what iv read in the studies, it has the best chance of being adapted into front line screening in prostate cancer, in conjunction with PSA. Mainly because the PSA score is a very vague indicator but in conjunction with parsortix and CTC analysis would become a lot more accurate.
not an expert on this topic yuyus but I'l give you my ideas
In breast cancer the mammogram is the current screening tool - no mass, no cancer i guess. But lots of women will find masses on mammograms. that where parosortix would come into the screening process instead of going straight to a potential biopsy or masectomy. Same idea Newland mentioned with pelvic masses
But for other cancers, who knows. Prostate cancer is a good one. PSA the current measure tbh isnt the greatest indicator, but it is cheap and easy to do. The thresholds are done by age eg 40-50, 50-60 but it is very easy for a man to have an elevated level as they get close to the end of the decade. But many men with an elevated PSA don't have cancer. Again i think i read a study where parsortix was compared to PSA and they said that used in combination it was very very useful. Again it would be useful for a biopsy too.
So there is potential for it to be used for screening. But what is used for screening at the end of the day comes down to money.
An example of this is a pie in the sky study in the UK that said anyone with early symptoms of lung cancer should receive an MRI to rule out potential masses in the lungs. Sounds great in practice but early symptoms of lung cancer are very vague and can be mild, it would mean that basically anyone with a cough would need an MRI. I would end up costing the NHS billions every year. You would potentially extend a few lives every year but would probably need to add on an extra 1% to our level of taxation. This however isnt an issue in America, where people pay for the best treatment and screening
So in America they tend to have better cancer care and treatment because the amount of money invested in finding better care and better screening. They are more likely to adapt parsortix into a cancer screening system if it shows results regardless of the costs.
Britain would probably adopt it ten years later if a overwhelming amount of evidence showed its benefit and the cost wasn't as much as previously.
Parsortix has a big advantage over so many other systems because the technology doesn't cost an arm and leg as phantom said. If it showed utility in screening and was adapted worldwide along with secondary confirmation and follow up testing you would be looking at one of the biggest companies there is
I don't think FDA is approving as a screening device. I am assuming Parsortix will be used along side a scan if you suspect a tumor. I think it is about an hour to run a test including clean up